Artelo Biosciences (Artelo Biosciences) Forward Dividend Yield % : 0.00% (As of Jun. 06, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Forward Dividend Yield %?

As of today (2024-06-06), the Forward Annual Dividend Yield of Artelo Biosciences is 0.00%.

As of today (2024-06-06), the Trailing Annual Dividend Yield of Artelo Biosciences is 0.00%.

ARTLW's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful Forward Dividend Yield % only.

Artelo Biosciences's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Artelo Biosciences's Forward Dividend Yield %

For the Biotechnology subindustry, Artelo Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artelo Biosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Forward Dividend Yield % falls into.

Artelo Biosciences Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Artelo Biosciences (NAS:ARTLW) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Artelo Biosciences Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.